Relationship between CMV and graft rejection after heart transplantation.
This study, which included 153 heart transplant patients, was designed to determine whether the cytomegalovirus (CMV) status of both donor and recipient may influence graft rejection. The follow-up was 1 year and they all received the same triple-drug immunosuppressive regimen with induction (antilymphocyte serum). There was no difference in the total rejection rate, but an increase in repeated rejection rate was shown in transplant recipients with hearts from CMV seropositive donors (P < 0.05). These data strongly suggest the impact of CMV in enhancement but not in induction of rejection. To prevent iterative rejection in the CMV seropositive donor group, antiviral therapy could be proposed during enhancement of antirejection therapy.
Decoene
C
C
Service d'Anesthesie-Reanimation Cardiovasculaire, Lille, France.
Pol
A
A
Dewilde
A
A
Wattre
P
P
Coppin
M C
MC
Gosselin
B
B
Stankowiak
C
C
Warembourg
H
H
D003586:Cytomegalovirus Infections / Q000150:complications*; D006084:Graft Rejection / Q000209:etiology*; D016027:Heart Transplantation / Q000009:adverse effects*; D006801:Humans